Bhavnani Sujata M, Ambrose Paul G, Jones Ronald N
Cognigen Corp., Buffalo, NY 14221-5831, USA.
Ann Pharmacother. 2002 Mar;36(3):530-2. doi: 10.1345/aph.1A419.
We believe, especially in an era of increasing antimicrobial resistance, that the integration of PK/PD models and stochastic techniques provides a powerful new tool to clinicians, researchers, and regulatory agencies alike. By using techniques such as these, we can begin to level the playing field so that PK/PD measures for therapeutic agents can be more accurately compared with greater certainty, and not be limited to discussions of susceptibility method variation or comparisons of MIC results.
我们相信，尤其是在抗菌药物耐药性不断增加的时代，药代动力学/药效学（PK/PD）模型与随机技术的整合为临床医生、研究人员和监管机构提供了一个强大的新工具。通过使用此类技术，我们可以开始营造公平竞争的环境，从而能够更准确、更确定地比较治疗药物的PK/PD指标，而不仅限于讨论药敏方法的差异或最低抑菌浓度（MIC）结果的比较。
